Weekly docetaxel as second-line therapy for patients with advanced breast cancer resistant to previous anthracycline treatment

Journal of Chemotherapy

Volumn 15, Issue 2, 2003, Pages 192-197

  Ramos, Manuel ^a   Gonzalez Ageitos A ^b   Amenedo, M ^a   Gonzalez Quintas A ^a   Gamazo, J L ^a   Togores, P ^a   Losada, G ^a   Almanza, C ^b   Romero, C ^b   Gomez Martin C ^b  

^a Centro Oncologico de Galicia   (Spain)

^b Epilepsy Unit   (Spain)

Author keywords

Advanced breast cancer; Anthracyclines; Second line chemotherapy; Weekly docetaxel

Indexed keywords

ANTHRACYCLINE; DOCETAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASTHENIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CAUSE OF DEATH; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SCREENING; EYE DISEASE; EYELID EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEMATOLOGIC DISEASE; HUMAN; LUNG FIBROSIS; NAIL DISEASE; NAUSEA; NEUTROPENIA; PAIN; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; SENSORY DYSFUNCTION; SKIN TOXICITY; SURVIVAL TIME; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0037613783     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2003.15.2.192     Document Type: Article

References (25)

1. Chevallier B, Fumoleau P, Kerbrat P, et al. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: A phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 1995; 13(2): 314-322.
2. Hudis CA, Seidman AD, Crown JP, et al. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14(1): 58-65.
3. Trudeau ME, Eisenhauer EA, Higgins BP, et al. Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 1996; 14(2): 422-428.
4. Ravdin PM, Burris HA, 3rd, Cook G, et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 1995; 13(12): 2879-2885.
5. Valero V, Holmes FA, Walters RS, et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995; 13(12): 2886-2894.
6. Baselga J, Tabernero JM. Weekly docetaxel in breast cancer: applying clinical data to patient therapy. Oncologist 2001; 6(Suppl 3): 26-29.
7. Seidman AD, Hudis CA, Albanel J, et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 1998; 16(10): 3353-3361.
8. Hainsworth JD, Burris HA, 3rd, Greco FA. Weekly administration of docetaxel (Taxotere): summary of clinical data. Semin Oncol 1999; 26 (3 Suppl 10): 19-24.
9. Hainsworth JD, Burris HA, 3rd, Erland JB, Thomas M, Greco FA. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 1998; 16(6): 2164-2168.
10. Tomiak E, Piccart MJ, Kerger J, et al. Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. J Clin Oncol 1994; 12(7): 1458-1467.
11. Hainsworth JD, Burris HA, 3rd, Yardley DA, et al. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 2001; 19(15): 3500-3505.
12. Burstein HJ, Manola J, Younger J, et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000; 18(6): 1212-1219.
13. Stemmler HJ, Gutschow K, Sommer H, et al. Weekly docetaxel (Taxotereo) in patients with metastatic breast cancer. Ann Oncol 2001; 12(10): 1393-1398.
14. Aihara T, Kim Y, Takatsuka Y. Phase II study of weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 2002; 13(2): 286-292.
15. Climent MA, Ruiz A, Llombart-Cussac A. Weekly docetaxel in patients with advanced malignancies. Toxicity profile and activity results. Proc Am Soc Clin Oncol 1999; 18: 453a.
16. Loeffler TM, Freund W, Hausamen TU. Activity of weekly Taxotere (TXT) in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 1998; 17: 113a.
17. Ramos M, Gonzalez-Ageitos A, Vicente J. Weekly docetaxel (D) for metastatic breast cancer (MBC) progressing after anthracyclines treatment. Proc Am Soc Clin Oncol 2000; 19: 445a.
18. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47(1): 207-214.
19. Guidelines for the reporting of adverse drug reactions. Bethesda: Division of Cancer Treatment, National Cancer Institute; 1988.
20. Figgitt DP, Wiseman LR. Docetaxel: an update of its use in advanced breast cancer. Drugs 2000; 59(3): 621-651.
21. O'Brien ME, Leonard RC, Barrett-Lee PJ, Eggleton SP, Bizzari JP. Docetaxel in the community setting: an analysis of 377 breast cancer patients treated with docetaxel (Taxotere) in the UK. UK Study Group. Ann Oncol 1999;10(2):205-210.
22. Cortes JE, Pazdur R. Docetaxel. J Clin Oncol 1995; 13(10): 2643-2655.
23. Kim Y, Takatsuka Y, Tanigawara Y, et al. Weekly docetaxel for patients with recurrent breast cancer: clinical results and pharmacokinetic/pharmacodynamic assessment. Proc Am Soc Clin Oncol 2000; 19: 436a.
24. Esmaeli B, Hortobagyi G, Esteva F, et al. Canalicular stenosis secondary to weekly docetaxel: a potentially preventable side effect. Ann Oncol 2002; 13(2): 218-221.
25. Jackisch C, Eibach HW, Kunth A, et al. Phase-II trial of docetaxel weekly as dose sense treatment in metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2000; 19: 417a.